• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Signalling >Crosstalk between the M-1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?
【24h】

Crosstalk between the M-1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?

机译：M-1毒蕈碱乙酰胆碱受体和内瘤素体系之间的串扰：与阿尔茨海默病的相关性？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alzheimer's disease (AD) is a neurodegenerative disorder which accounts for 60-70% of the 50 million world-wide cases of dementia and is characterised by cognitive impairments, many of which have long been associated with dysfunction of the cholinergic system. Although the M-1 muscarinic acetylcholine receptor (mAChR) is considered a promising drug target for AD, ligands targeting this receptor have so far been unsuccessful in clinical trials. As modulatory receptors to cholinergic transmission, the endocannabinoid system may be a promising drug target to allow fine tuning of the cholinergic system. Furthermore, disease-related changes have been found in the endocannabinoid system during AD progression and indeed targeting the endocannabinoid system at specific disease stages alleviates cognitive symptoms in numerous mouse models of AD. Here we review the role of the endocannabinoid system in AD, and its crosstalk with mAChRs as a potential drug target for cholinergic dysfunction.
机译：阿尔茨海默病（AD）是一种神经变性障碍，其占全球痴呆症患者的50-70％，其特征在于认知障碍，其中许多长期与胆碱能系统的功能障碍有关。 虽然M-1毒蕈碱乙酰胆碱受体（MACRR）被认为是AD的有希望的药物靶标，但靶向该受体的配体已经在临床试验中未能成功。 作为胆碱能速率的调节受体，内胆碱系统可以是有希望的药物靶标，以允许胆碱能系统进行微调。 此外，在AD进展期间，在Endonocannabinoid系统中发现了与疾病相关的变化，并且实际上靶向特定疾病阶段的内胆蛋白系统可减轻广告的许多小鼠模型中的认知症状。 在这里，我们审查了Endocannabinoid系统在AD中的作用，以及其与MACHRS作为胆碱能功能障碍的潜在药物靶标的串扰。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号